Target intelligence / Profile preview

Alpha-3 beta-4 nicotinic acetylcholine receptor (α3β4 nAChR)

Target
α3β4 nAChR
Molecular classification
Ion channel, Receptor, Ligand-gated ion channel
01

Overview

The alpha-3 beta-4 (α3β4) nicotinic acetylcholine receptor is a subtype of pentameric ligand-gated ion channels primarily composed of α3 and β4 subunits. It is highly expressed in the autonomic ganglia, adrenal medulla, and specific brain regions such as the medial habenula and interpeduncular nucleus. In the peripheral nervous system, it acts as the principal ganglionic receptor mediating fast synaptic transmission, whereas in the central nervous system, it plays a critical role in modulating reward pathways and neurotransmitter release.

Due to its localization in the habenulo-interpeduncular tract, the α3β4 receptor has emerged as a key therapeutic target for substance use disorders, particularly nicotine, cocaine, and opioid addiction, where receptor inhibition has been shown to reduce drug-seeking behavior and withdrawal symptoms. Additionally, it is investigated for its involvement in overactive bladder, depression, and neuropathic pain. Pharmacological agents targeting this receptor include agonists like nicotine and cytisine, as well as non-competitive antagonists such as mecamylamine, dexmecamylamine (TC-5214), and 18-methoxycoronaridine (18-MC). However, drug development faces significant challenges, as off-target activity or systemic inhibition of ganglionic α3β4 receptors can lead to autonomic side effects, including cardiovascular fluctuations, gastrointestinal issues, and urinary retention.

Other names
alpha3beta4 nicotinic acetylcholine receptorα3β4 nicotinic receptorGanglion-type nicotinic receptorGanglionic nicotinic receptorCHRNA3-CHRNB4 nicotinic acetylcholine receptor
02

Mechanism of action

Non-competitive antagonism, agonism, partial agonism, negative allosteric modulation

03

Biological functions

Signal transductionSynaptic transmissionIon transportNeurotransmission
04

Disease associations

AddictionNeurodegenerative diseaseOveractive bladderDepressionPain
05

Safety considerations

Autonomic side effects [1.2.3]Cardiovascular toxicity (tachycardia, hypertension)Urinary retentionGastrointestinal distress (constipation, nausea)Postural hypotension
06

Interacting drugs

11 more in the full profile.

07

Biomarkers

CHRNA3 genetic variants (e.g., rs1051730) [4.1.4]CHRNB4 genetic variantsCHRNA5-CHRNA3-CHRNB4 gene cluster polymorphisms (e.g., rs16969968)

Beyond the preview

Go deeper on Alpha-3 beta-4 nicotinic acetylcholine receptor (α3β4 nAChR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha-3 beta-4 nicotinic acetylcholine receptor (α3β4 nAChR).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call